

Announcement Summary

Entity name

PHARMAXIS LTD

Date of this announcement

Wednesday November 29, 2023

The +securities the subject of this notification are:

😇 +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
PXSAAS	PERFORMANCE RIGHTS	2,771,000	29/11/2023

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

PHARMAXIS LTD

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type ABN Registration number 75082811630

1.3 ASX issuer code PXS

1.5 Date of this announcement

29/11/2023



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

C +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

☑ has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to

ASX in an Appendix 3B

ACV		
ASX +security code and descripting PXSAAS : PERFORMANCE RIGHT		
Date the +securities the subject of 29/11/2023	f this notification were issued	
Will these +securities rank equall +securities in that class ⓒ Yes	y in all respects from their issue date v	vith the existing issued
Were any of the +securities issue ⓒ Yes	d to +key management personnel (KMI	P) or an +associate?
Provide details of the KMP or +as	sociates being issued +securities.	
Name of KMP	Name of registered holder	Number of +securities
Gary Phillips	same	2,771,000
Place provide a LIPL link for a d	ocument lodged with ASX detailing the	terms of the +employee incentive scheme
or a summary of the terms		
or a summary of the terms	ets/Documents/pdf/02023/ASX/2023-10-2	26-PXS-2023-AGM-NoM.pdf
or a summary of the terms https://www.pharmaxis.com.au/ass	ets/Documents/pdf/02023/ASX/2023-10-2	<u>.</u>
or a summary of the terms https://www.pharmaxis.com.au/ass		<u>.</u>
or a summary of the terms https://www.pharmaxis.com.au/ass		<u>.</u>

Issue details

Number of	+securities
2,771,000	



Part 4 - +Securities on issue

 Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:

 (A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

 4.1 Quoted +Securities (Total number of each +class of +securities quoted)

 ASX +security code and description

 PXS : ORDINARY FULLY PAID

 722,614,210

 4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
PXSAAT : OPTION EXPIRING 01-DEC-2027 EX \$0.11	5,000,000
PXSAAS : PERFORMANCE RIGHTS	37,343,895



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? ☑ No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

C Yes

5.2a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

28/11/2023